Poster Session II - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.01 - ACUTE MANAGEMENT - Neither thrombolysis nor thrombectomy P715 - ESOC25-1188 EFFECTIVENESS OF EDARAVONE DEXBORNEOL IN REAL-WORLD PATIENTS WITH MODERATE AND SEVERE ACUTE ISCHEMIC STROKE Yifan Wu 1 , Gaoting MA 1 , Ran Mo 1 , Yingting Zuo 1 , Haiqing Song 1 , Lianmei Zhong 1 1 Xuanwu Hospital Capital Medical University, Beijing, China Background and Aims: Edaravone dexborneol is a novel neuroprotective agent widely used for acute ischemic stroke (AIS) patients in China
From this perspective, innovative therapies have broadened treatment prospects, especially for chronic diseases
Patients typically experience appetite suppression within the first two weeks and measurable weight reduction by week eight
Below is a clear breakdown of recommended dosages and their effects based on current research: 1 mg is the lower end, with mild appetite suppression and smaller weight loss seen in clinical trials
You may also want an exercise mat for comfort
Business Description Product Portfolio Strategic Alliances or Partnerships Recent Developments Financial Details Others Sanofi Business Description Product Portfolio Strategic Alliances or Partnerships Recent Developments Financial Details Others GlaxoSmithKline plc Business Description Product Portfolio Strategic Alliances or Partnerships Recent Developments Financial Details Others Boehringer Ingelheim International GmbH Business Description Product Portfolio Strategic Alliances or Partnerships Recent Developments Financial Details Others Amgen Inc